Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Non-Current Debt (2022 - 2025)

Cue Biopharma's Non-Current Debt history spans 4 years, with the latest figure at $190000.0 for Q3 2025.

  • For Q3 2025, Non-Current Debt fell 85.69% year-over-year to $190000.0; the TTM value through Sep 2025 reached $190000.0, down 85.69%, while the annual FY2023 figure was $4.2 million, 47.7% down from the prior year.
  • Non-Current Debt for Q3 2025 was $190000.0 at Cue Biopharma, roughly flat from $190000.0 in the prior quarter.
  • Across five years, Non-Current Debt topped out at $9.9 million in Q2 2022 and bottomed at $190000.0 in Q2 2025.
  • The 4-year median for Non-Current Debt is $5.2 million (2023), against an average of $5.1 million.
  • The largest annual shift saw Non-Current Debt fell 28.23% in 2023 before it plummeted 91.69% in 2025.
  • A 4-year view of Non-Current Debt shows it stood at $8.0 million in 2022, then plummeted by 47.7% to $4.2 million in 2023, then plummeted by 68.4% to $1.3 million in 2024, then tumbled by 85.69% to $190000.0 in 2025.
  • Per Business Quant, the three most recent readings for CUE's Non-Current Debt are $190000.0 (Q3 2025), $190000.0 (Q2 2025), and $1.3 million (Q3 2024).